Open AccessNeoadjuvant Paradigm for Accelerated Drug Development: An Ideal Model in Bladder Cancer
Author(s) -
Chism David D.,
Woods Michael E.,
Milowsky Matthew I.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0023
Subject(s) - medicine , bladder cancer , oncology , drug development , disease , clinical trial , neoadjuvant therapy , pathological , chemotherapy , drug , cancer , bioinformatics , pharmacology , breast cancer , biology
Learning ObjectivesDescribe how pathological complete response predicts for improved outcome in patients with MIBC. Explain the biological rationale for neoadjuvant chemotherapy in MIBC related to the dysregulation in PI3K/AKT, RAF/MEK/ERK signaling pathways, and ERBb family.